Department of Life Sciences, University of Siena, 53100 Siena, Italy.
Dipartimento NEUROFARBA, Sezione di Scienze Farmaceutiche, Università di Firenze, Sesto Fiorentino, 50139 Firenze, Italy.
Int J Mol Sci. 2020 Apr 23;21(8):2983. doi: 10.3390/ijms21082983.
Carbonic anhydrase IX (CA-IX) plays a pivotal role in regulation of pH in tumor milieu catalyzing carbonic acid formation by hydrating CO. An acidification of tumor microenvironment contributes to tumor progression via multiple processes, including reduced cell-cell adhesion, increased migration and matrix invasion. We aimed to assess whether the pharmacological inhibition of CA-IX could impair tumor cell proliferation and invasion. Tumor epithelial cells from breast (MDA-MB-231) and lung (A549) cancer were used to evaluate the cytotoxic effect of sulfonamide CA-IX inhibitors. Two CA-IX enzyme blockers were tested, SLC-0111 (at present in phase Ib clinical trial) and AA-06-05. In these cells, the drugs inhibited cell proliferation, migration and invasion through shifting of the mesenchymal phenotype toward an epithelial one and by impairing matrix metalloprotease-2 (MMP-2) activity. The antitumor activity was elicited via apoptosis pathway activation. An upregulation of p53 was observed, which in turn regulated the activation of caspase-3. Inhibition of proteolytic activity was accompanied by upregulation of the endogenous tissue inhibitor TIMP-2. Collectively, these data confirm the potential use of CA-IX inhibitors, and in particular SLC-0111 and AA-06-05, as agents to be further developed, alone or in combination with other conventional anticancer drugs.
碳酸酐酶 IX(CA-IX)在调节肿瘤环境中的 pH 值方面发挥着关键作用,通过水合 CO 催化碳酸的形成。肿瘤微环境的酸化通过多种过程促进肿瘤进展,包括降低细胞-细胞黏附、增加迁移和基质侵袭。我们旨在评估 CA-IX 的药理抑制是否会损害肿瘤细胞的增殖和侵袭。我们使用乳腺癌(MDA-MB-231)和肺癌(A549)的肿瘤上皮细胞来评估磺酰胺 CA-IX 抑制剂的细胞毒性作用。测试了两种 CA-IX 酶抑制剂,SLC-0111(目前处于 Ib 期临床试验)和 AA-06-05。在这些细胞中,药物通过将间充质表型向上皮表型转变,并通过抑制基质金属蛋白酶-2(MMP-2)活性,抑制细胞增殖、迁移和侵袭。抗肿瘤活性是通过激活细胞凋亡途径引起的。观察到 p53 的上调,反过来又调节了 caspase-3 的激活。蛋白酶活性的抑制伴随着内源性组织抑制剂 TIMP-2 的上调。综上所述,这些数据证实了 CA-IX 抑制剂,特别是 SLC-0111 和 AA-06-05,作为单独或与其他传统抗癌药物联合进一步开发的潜在用途。